2661481-41-8
Chemical Structure
Zilemaltib
Synonym(s): SGR-1505
- CAS No.: 2661481-41-8
- Formula:C18H12ClF4N9O
- Molecular Weight:481.79
InChIKey: DEMHKALZEXJNJH-QGZVFWFLSA-N
SMILES: FC(F)([C@]1(C2=C(C=NC3=CC(F)=NN32)N(C1)C(NC4=CN=C(N5N=CC=N5)C(Cl)=C4)=O)C)F
Biological Activity: SGR-1505 is an oral small molecule MALT1 inhibitor with anti-proliferative and antitumor activity.SGR-1505 inhibits MALT1 enzymatic activity to modulate NF-κB pathway gene expression.SGR-1505 induces modulation of cell cycle, DNA damage, and apoptosis-related genes in in vivo tumor samples.SGR-1505 exerts tumorostatic and regressive activity in ABC-DLBCL xenograft models.SGR-1505 can be used for the research of activated B cell-like diffuse large B cell lymphoma, non-Hodgkin B-cell lymphomas, chronic lymphocytic leukemia, and mature B cell neoplasms[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zilemaltib | 99.89% | SGR-1505 is an oral small molecule MALT1 inhibitor with anti-proliferative and antitumor activity.SGR-1505 inhibits MALT1 enzymatic activity to modulate NF-κB pathway gene expression.SGR-1505 induces modulation of cell cycle, DNA damage, and apoptosis-related genes in in vivo tumor samples.SGR-1505 exerts tumorostatic and regressive activity in ABC-DLBCL xenograft models.SGR-1505 can be used for the research of activated B cell-like diffuse large B cell lymphoma, non-Hodgkin B-cell lymphomas, chronic lymphocytic leukemia, and mature B cell neoplasms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wu Yin PhD, et al. Sgr-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile. Volume 142, Supplement 1, 2 November 2023, Page 2997.
- [2]. Feng S, et al., Cyclic compounds and methods of using same. WO2021134004.
- [3]. Adam Olszewski MD, et al A Phase 1, Open-Label, Muticenter, Dose-Escalation Study of Sgr-1505 As Monotherapy inSubjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102
